MedDataX Logo

A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome

NCT ID: NCT07181837

Last Updated: 2025-11-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1/PHASE2

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-10-29

Study Completion Date

2031-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety and efficacy of MVX-220 gene therapy in children and adults with Angelman syndrome with UBE3A gene deletion, uniparental disomy, or imprinting center defect genotypes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

MVX-220 is an investigational gene replacement therapy intended to provide a functional copy of the UBE3A gene to individuals with Angelman syndrome. This study is designed to evaluate the safety, tolerability and efficacy of MVX-220 in participants with Angelman syndrome who have deletion, uniparental disomy, or imprinting center disorder genotypes. The study has 2 primary cohorts: Cohort 1 that includes adults followed by Cohort 2 that includes children. All patients will receive a single dose of MVX-220 administered by injection into the cisterna magna. There is no control group and all individuals will receive the gene therapy. An independent data safety monitoring board will review the safety information from Cohort 1 before individuals can be enrolled in Cohort 2. An optional cohort of adults and/or children (Cohort 3) may be enrolled based on a review of data from Cohorts 1 and 2. All patients will be required to take steroids before and for a brief period during the study to help mitigate the risk of immune response to the gene therapy. Patients will be followed for safety and efficacy for an initial 2-year period post-treatment and then transition to less frequent monitoring schedule for an additional 3 years. The total duration of follow up in the study is 5 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Angelman Syndrome

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Angelman syndrome gene therapy AAV cisterna magna

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1: Adults ages 18-50

MVX-220, single dose intra cisterna magna injection

Group Type EXPERIMENTAL

MVX-220

Intervention Type GENETIC

AAVhu68 viral vector

Cohort 2: Children ages 4-8

MVX-220, single dose intra cisterna magna injection

Group Type EXPERIMENTAL

MVX-220

Intervention Type GENETIC

AAVhu68 viral vector

Cohort 3: Optional cohort, adults and children ages 4-50

MVX-220, single dose intra cisterna magna injection

Group Type EXPERIMENTAL

MVX-220

Intervention Type GENETIC

AAVhu68 viral vector

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MVX-220

AAVhu68 viral vector

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The participant's parent/legal guardian must provide written informed consent.
2. Symptoms consistent with AS and documented genetic confirmation of one of the following genotypes resulting in a diagnosis of AS:

1. Full maternal UBE3A gene deletion causing AS in the region of 15q11.2-q13
2. Uniparental disomy
3. Imprinting center defect
3. The participant must be 18 to 50 years of age, inclusive (for adult participants), or 4 to 8 years of age, inclusive (for pediatric participants), at Screening.
4. The participant must have the ability to ambulate independently.
5. The participant must be on stable antiepileptic medications (with no changes within 1 month prior to the Screening visit, except for weight associated dose adjustments).

Exclusion Criteria

1. Clinically significant medical finding other than AS, that, in the judgment of the Investigator would make the participant unsuitable for participation.
2. Laboratory abnormalities including but not limited to:

1. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> upper limit of normal (ULN)
2. Total and/or fractionated bilirubin (direct and/or indirect) \> ULN
3. Gamma-glutamyl transferase (GGT) \> ULN
4. Estimated glomerular filtration rate (eGFR) below the lower limit of normal (LLN) for age
5. Hemoglobin \< 8 g/dL
6. White blood cell (WBC) count outside the normal range for age
7. Platelet count \< LLN
8. Partial thromboplastin time (PTT) outside the reference range
9. PT/International normalized ratio (INR) outside the reference range
3. Any known history and/or family history of hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) or multisystem inflammatory syndrome (MIS).
4. Any known history and/or family history of disordered complement function and/or complement gene mutation(s).
5. History of systemic lupus erythematous, Still's disease, rheumatoid arthritis, and/or other severe autoimmune conditions per judgment of the Investigator.
6. Any known history of thrombotic microangiopathy (TMA)/microangiopathic hemolytic anemia, or hypercoagulable conditions including, but not limited to, disseminated intravascular coagulation (DIC), deep venous thrombosis, and pulmonary embolism.
7. Current therapy with high dose immunosuppressants.
8. Prior or current treatment with an investigational drug within 6 months or 5-half-lives of the hospital admission whichever is longer.
9. Prior treatment with an antisense oligonucleotide within 1 year of hospital admission.
10. A history of gene therapy administration.
11. Any contraindication to ICM administration procedure, including contraindications to imaging, contrast use, anesthesia, or any condition that would increase the risk of adverse outcomes from the ICM procedure.
12. Any contraindication to glucocorticoid use
Minimum Eligible Age

4 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

MavriX Bio, LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Rush University Medical Center

Chicago, Illinois, United States

Site Status RECRUITING

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

MavriX Bio, LLC

Role: CONTACT

Phone: 978-538-8554

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Milana Milic

Role: primary

Ive Muse

Role: primary

Hansen

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MVX-AAV-101

Identifier Type: -

Identifier Source: org_study_id